The efficacy and safety of intensified enteric‐coated mycophenolate sodium with low exposure of calcineurin inhibitors in Chinese de novo kidney transplant recipients: a prospective study

The aim of this study was to investigate the efficacy and safety of a transient intensified enteric‐coated mycophenolate sodium (EC‐MPS) dosing regimen with low exposure of calcineurin inhibitors (CNIs) in Chinese de novo kidney transplantation.

[1]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[2]  D. Hesselink,et al.  Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[3]  L. Cai,et al.  A single‐centre, open‐label, prospective study of an initially short‐term intensified dosing regimen of enteric‐coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live‐donor kidney transplant recipients , 2014, International journal of clinical practice. Supplement.

[4]  D. Roth,et al.  Corticosteroid and calcineurin inhibitor sparing regimens in kidney transplantation. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  K. Budde,et al.  A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. , 2013, Clinical nephrology.

[6]  L. Rostaing,et al.  A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. , 2012, Clinical nephrology.

[7]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[8]  A. Sharif,et al.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. , 2011, Journal of the American Society of Nephrology : JASN.

[9]  K. Budde,et al.  Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients , 2011, Transplantation.

[10]  B. Kiberd,et al.  The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[11]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[12]  D. Adu,et al.  Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis , 2009, Transplantation.

[13]  J. D. de Fijter,et al.  Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial , 2008, Transplantation.

[14]  H. Ekberg.  Calcineurin Inhibitor Sparing in Renal Transplantation , 2008, Transplantation.

[15]  G. Einecked,et al.  Banff 07 Classification of Renal Allograft Pathology : Updates and Future Directions , 2008 .

[16]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[17]  P. Marquet,et al.  Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  B. Nashan,et al.  Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  L. Rostaing,et al.  Impact of Cyclosporine Reduction With MMF: A Randomized Trial in Chronic Allograft Dysfunction. The ‘Reference’ Study , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  J. Trotter,et al.  Immunosuppression: Evolution in Practice and Trends, 1994–2004 , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  B. Kiberd,et al.  Early Adequate Mycophenolic Acid Exposure is Associated with Less Rejection in Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  L. Weber,et al.  The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. , 2002, Journal of the American Society of Nephrology : JASN.